Last reviewed · How we verify
severe alopecia areata — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Leqselvi | DEURUXOLITINIB | Sun Pharm Inds Inc | JAK1, JAK2, TYK2 | 2024-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Sun Pharm Inds Inc · 1 drug in severe alopecia areata
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in severe alopecia areata:
- severe alopecia areata treatment updates — RSS
- severe alopecia areata treatment updates — Atom
- severe alopecia areata treatment updates — JSON
Cite this brief
Drug Landscape (2026). severe alopecia areata — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/severe-alopecia-areata. Accessed 2026-06-10.
Related
- severe alopecia areata full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing